NCT01611623View on ClinicalTrials.gov

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

March 31, 2013

Conditions
Cancer
Interventions
DRUG

SNX-5422

Tablets dose every other day; dose escalation based on safety

All Listed Sponsors
lead

Esanex Inc.

INDUSTRY

NCT01611623 - Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies | Biotech Hunter | Biotech Hunter